Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

What Was Tested

Researchers studied Amylin (Islet Amyloid Polypeptide) and Amycretin in this randomized controlled trial publication.

Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist.

Who Took Part

The study group was 36 participants.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Participants were randomly allocated to receive amycretin or placebo, with participants and investigators masked to trial product allocation.

The primary endpoint was the number of treatment-emergent adverse events measured from baseline to end of study (Parts A-E).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Amylin (Islet Amyloid Polypeptide) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Amylin (Islet Amyloid Polypeptide).

A placebo (an inactive look-alike) gave the Amylin (Islet Amyloid Polypeptide) group a baseline to be compared against.

The study took place at a single clinical research centre in San Antonio, TX, USA.

Secondary endpoints were area under the plasma concentration-time curve, maximum plasma concentration, and relative change in bodyweight from baseline.

The safety analysis set comprised all participants exposed to treatment, and the full analysis set comprised all randomly allocated participants.

This study is registered with ClinicalTrials.gov, NCT06064006.

What Was Measured

Topics PubMed links to this paper include Obesity, Amylin Receptor Agonists, Overweight, Glucagon-Like Peptide-1 Receptor Agonists and Islet Amyloid Polypeptide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide) and Amycretin in 36 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Lancet (London, England)), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page and the Amycretin compound page, all human trials.